The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial.
A. Lopez-Pousa
No relevant relationships to disclose
B. Bui Nguyen
No relevant relationships to disclose
X. Garcia del Muro
No relevant relationships to disclose
J. Martin Broto
No relevant relationships to disclose
C. Balañá
No relevant relationships to disclose
J. Lavernia
No relevant relationships to disclose
J. Cruz
No relevant relationships to disclose
J. Maurel
No relevant relationships to disclose
R. Andres
No relevant relationships to disclose
C. M. Valverde
No relevant relationships to disclose
J. Fra
No relevant relationships to disclose
J. Martinez-Trufero
No relevant relationships to disclose
J. A. Lopez-Martin
No relevant relationships to disclose
I. Sevilla
No relevant relationships to disclose
R. Cubedo
No relevant relationships to disclose
J. Blay
No relevant relationships to disclose